Porter & Co.'s 'Ignition Point' — The Five Gene-Silencing Stocks Behind the Lp(a) Boom

The Hook

Porter Stansberry has renamed his biotech letter again, and the new name is part of the pitch. The letter that launched as Biotech Frontiers in 2024, then broadened into Tech Frontiers, is now Porter & Co. Biotechnology. The change follows the summer departure of Erez Kalir, the letter’s previous lead analyst, and Porter himself is now fronting it. The “Ignition Point” presentation, subtitled “How I’m Playing the AI Melt-Up and Down,” is his opening argument.

The framing is a coming biotech boom powered by what Porter calls the “second wave of artificial intelligence.” The urgency hook is the one he has used for years, recycled with minor adjustments: “This is the largest infrastructure build-out in America since the railroad boom. You know fortunes will be made, fortunes measured in trillions of dollars. But what you don’t know is: most investors are about to lose everything.”

Strip away the fear language and the actual thesis is more interesting than the marketing. Porter is selling a “barbell” portfolio for biotech: royalty “tollbooth” companies as the ballast on one end, and speculative “first-in-class” drug developers as the home-run swing on the other. The core theme is what he calls the “Kingdom of Gene Silencing,” aimed at a massive and mostly untreated cardiovascular target: lipoprotein(a), better known as Lp(a). We have a separate explainer on what Lp(a) is and why statins can’t touch it, but the short version is that it is a genetically driven cholesterol variant that diet and exercise barely move, which makes it a genuinely hard target and a natural fit for gene-silencing drugs.

The Big Claim

The report promises four “Ignition Point” recommendations in the gene-silencing space, plus a bonus special report. Here is the exact tease:

“This report contains the names, ticker symbols, and entry prices for our first four ‘Ignition Point’ recommendations. Focused on a massive, untreated cardiovascular disease, you’ll get the details on our #1 Ballast, our Anchor, our Challenger, and a speculative Lightning Strike trading near $11 whose therapy has, in trials reported to date, reduced markers of the disease down by up to 99%.”

The four core picks, decoded by Stock Gumshoe, are Novartis (NVS) as the Ballast, Alnylam (ALNY) as the Anchor, Arrowhead (ARWR) as the Challenger, and Silence Therapeutics (SLN) as the Lightning Strike. The bonus report, “The NVIDIA of Medicine,” resolves to Eli Lilly (LLY). That is five names total, spread across the barbell from a roughly $269 billion pharma giant down to a roughly $750 million small-cap.

The Mechanism

The scientific story is real and worth understanding on its own terms. Lp(a) is a genetically driven form of cholesterol that diet and exercise barely move. Because your Lp(a) level is mostly set by your genes, it has been a notoriously hard target for traditional statins. That makes it a natural fit for gene-silencing drugs, which shut down the genes that produce the protein in the first place. We walked through how RNA interference works in a separate piece, and it is the technical backbone of every pick in this report.

The Ballast is Novartis (NVS). The tease describes “the $150 billion Titan that is running the very first trial ever to prove lowering Lp(a) prevents cardiovascular events.” That trial is for pelacarsen, an antisense drug Novartis licensed from Ionis Pharmaceuticals. Novartis is a genuine pharma giant with roughly $60 billion in annual revenue and a diversified business that is not a single bet on Lp(a).

The Anchor is Alnylam (ALNY). This is the RNA-interference pioneer founded in 2002 that holds the broad Tuschl II patents covering the design of silencing molecules themselves. Alnylam spent two decades solving the delivery problem, and today it has actual commercial drugs led by Amvuttra. It is no longer a promise story; it has revenue. We have a fuller breakdown of the Alnylam business.

The Challenger is Arrowhead (ARWR). Arrowhead’s TRiM platform aims to take gene silencing out of the liver and into muscle, fat, lung, and brain tissue. It has signed multi-billion-dollar deals and is slowly becoming a commercial company with its Redemplo launch for a rare lipid disorder.

The Lightning Strike is Silence Therapeutics (SLN). This is the ~$11 small-cap, trading near a $750 million market cap. Its drug zerlasiran achieved up to a 99% reduction in Lp(a) in a Phase I trial. That is the “99%” in the tease.

The bonus is Eli Lilly (LLY), pitched as “the most dominant platform company in medicine” on the strength of its oral weight-loss pill Foundayo (orforglipron), approved in April 2026.

The four royalty “tollbooth” companies Porter uses to describe the ballast end of the barbell (Royalty Pharma, Ligand, Halozyme, and XOMA Royalty) are discussed in the pitch but kept out of the tracking data because it is genuinely unclear whether they are formal recommendations or just context. The royalty concept is the same one we broke down in his Royalty Riches teardown, and it is the sturdiest part of the barbell.

The Real Picks

Prices are the September 23, 2026 close. Four of the five picks have ticked up slightly since the promo first ran. The Lightning Strike, Silence Therapeutics, is down about 8% from its tease price, which is exactly the kind of volatility you should expect from a $750 million market-cap biotech.

Does the Math Check Out?

Here is the problem, and it is a big one. The promo leads with the Ballast pick, and the Ballast’s proof has already broken.

On September 4, Novartis reported the initial results of the pelacarsen trial: an endpoint failure. The drug did exactly what it was designed to do biologically, slashing Lp(a) levels in the blood. But across more than 8,300 patients followed for years, it did not reduce real-world cardiovascular events, heart attacks, strokes, or cardiac death, compared to a placebo. The promo was almost certainly recorded before that result, because it describes Novartis as “running the very first trial ever to prove lowering Lp(a) prevents cardiovascular events.” It did not prove that.

That matters for three of the four picks, not just one. The Lightning Strike, SLN, is sold on a “99% reduction” in Lp(a), but Lp(a) is a biomarker, not a clinical outcome. The tease itself says it “reduced markers of the disease,” which is precisely the surrogate that the Novartis failure just showed may not translate into fewer events. SLN has no Phase 3 partner for zerlasiran and is holding off on that expensive trial until it finds one to pay for it. The Challenger, ARWR, sold its royalty rights on olpasiran (Amgen’s Lp(a) drug) to Royalty Pharma for $250 million, so its Lp(a) exposure is now milestone-linked rather than a royalty stream.

To be fair, the theory is not dead. Amgen’s olpasiran and Lilly’s lepodisiran are seen as more powerful, producing bigger Lp(a) reductions than pelacarsen. Lilly got lepodisiran through its Dicerna acquisition and a Novo Nordisk partnership, so their results could still differ. But the risk that reducing Lp(a) simply does not reduce cardiac risk has gone from theoretical to concrete.

On the valuation side, the picks are more reasonable than the hype would suggest. Alnylam trades around 23 times forward earnings with EPS expected to grow from roughly $9 in 2026 to $15 in 2028. Novartis is a diversified giant, not a leveraged bet. Lilly at about 30 times forward earnings with roughly 20% expected growth is a quality compounder, but calling it “The NVIDIA of Medicine” is a stretch, since NVIDIA’s multiple was backed by triple-digit growth, not 20%.

The genuinely speculative names are appropriately risky. ARWR has roughly $450 million in expected 2026 revenue against a $10 billion market cap and is not profitable. SLN has no meaningful revenue and enough cash to last through 2028, but every early-stage drug developer is one bad readout away from a repricing. Porter sizes the Lightning Strike at a 2% “speculative allocation,” which is honest.

What They Got Right

1. The barbell structure is genuinely good risk management. Pairing durable royalty compounders with a small speculative sleeve is a coherent way to hold biotech exposure without depending on any single trial readout.
2. The “just be in the sector” insight is real. Porter’s own commentary that “most of the alpha is generated by simply buying the sector when it’s running” is the most honest thing in the pitch, and it is well supported by biotech’s history of cyclical booms.
3. The names are quality, not shells. Novartis, Alnylam, and Lilly are real leaders with real products and real revenue. This is not a penny-stock grab bag.
4. He is honest about the risk. The presentation explicitly says “there will still be losses” and sizes the speculative pick at 2%, which is a level of candor many promos never reach.

What They Got Wrong

1. The lead pick’s proof already failed. Pelacarsen’s endpoint failure on September 4 directly contradicts the tease’s claim that Novartis is running “the very first trial ever to prove lowering Lp(a) prevents cardiovascular events.” The ad copy reads as if that result never happened.
2. A biomarker is being sold as an outcome. The “99% reduction” for Silence Therapeutics is a reduction in Lp(a), a surrogate marker, in a Phase I trial of a drug with no Phase 3 partner. The Novartis failure is exactly the scenario where a biomarker moves but outcomes do not.
3. Stale numbers undercut the credibility. “The $150 billion Titan” is really a ~$269 billion company, and Alnylam’s revenue guidance was trimmed to $5.1 billion, not raised to the “$5.3 billion” the tease cites.
4. “Most investors are about to lose everything” is a fear hook, not analysis. It is the same doomsday framing used to sell subscriptions for years, and it sits awkwardly next to Porter’s own argument that the sector, broadly owned, is where the money is made.

The Verdict

The barbell concept is sound, and the large-cap names are defensible. But do not buy the “Ignition Point” urgency. The story the promo leads with, gene silencing for Lp(a), already has a hole in it that the ad copy does not acknowledge. If you want biotech exposure, the honest takeaway from Porter’s own argument is that simply being in the sector during a bull market generates most of the alpha, which undercuts the “you need my four picks” framing.

The specific quality names (Novartis, Alnylam, and Lilly) are worth understanding on their own merits at the right price. The Lightning Strike is a lottery ticket, which is fine at 2%, but it is not a reason to act this week.

This is not financial advice. NewsletterVetter has no position in any stock mentioned. Stock Gumshoe discloses that it owns shares of Texas Pacific Land and NVIDIA and will not trade covered stocks for at least three days after publication. Porter & Co. Biotechnology is a paid subscription product, and the “Ignition Point” presentation is marketing for that product; its forward-looking claims about drug trials, valuations, and a “biotech bull market” are opinions, not guarantees.